P&G Health Q2 FY27: Standalone PAT Up 26% YoY to ₹111.5 Cr, Margins Expand, Tops Own Preview Range
PAT +25.94% YoY · revenue +17.72% · margins expanding
₹382.49 Cr
+17.72% YoY
₹111.51 Cr
+25.94% YoY
28.86%
+2pp YoY
₹67.18
Procter & Gamble Health's standalone PAT for Q2 FY27 (quarter ended September 30, 2026) came in at ₹111.51 Cr, up 25.9% YoY from ₹88.54 Cr and up 16.0% QoQ from ₹96.15 Cr. Revenue from operations rose 17.7% YoY to ₹382.49 Cr (from ₹324.92 Cr) and 5.2% QoQ (from ₹363.71 Cr). This quarter carries no exceptional item, unlike Q1 FY27 which had a ₹31.80 Cr one-off gain on the sale of the Worli office property — so the YoY comparison (also clean of one-offs on the Q2 FY26 side) is the cleanest read, and it shows a genuinely strong, non-one-off print rather than a base-effect illusion.
Q2 FY-2027 vs prior quarters
The margin story is operating leverage: total expenses grew only 12.1% YoY (₹210.85 Cr to ₹236.33 Cr) against 17.7% revenue growth, with cost of materials consumed actually flat-to-down and employee costs the main absolute increase. Net profit margin (PAT/total income) expanded to 28.9% from 26.8% a year ago and 26.2% last quarter — consistent expansion on both axes, pointing to price/mix holding up rather than the raw-material headwinds our pre-result preview had flagged as the key swing factor.
The stock went into the print at ₹5,954.5, up 7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
EPS ₹67.18 (basic/diluted) vs ₹53.34 year-ago and ₹57.92 prior quarter (the latter boosted by Q1's exceptional gain; ₹38.77 pre-exceptional is the cleaner QoQ base)
Tax expense ₹38.54 Cr, effective rate ~25.7% on PBT of ₹150.05 Cr
Cash and cash equivalents nearly doubled to ₹322.86 Cr (from ₹177.24 Cr at FY26-end), aided by ₹33.64 Cr proceeds from the Worli property sale completed in Q1
Against our own pre-result preview — which pencilled in revenue of ₹350–365 Cr, an EBITDA margin watch of 26–27%, and normalized PAT growth of 8–12% off a soft Q1 (+7% revenue growth, margin pressure) — the actual print beats on every count: revenue above the range, and 25.9% YoY PAT growth roughly 2-3x the normalized growth the Street-thin preview had penciled in. The preview's watch items are resolved in the company's favour: revenue growth reaccelerated rather than stayed muted, and margins expanded rather than stayed under pressure. On the third watch item — full-year guidance — the company gives none on record, as before; management offers no formal outlook in this filing, consistent with its historical pattern of not guiding. A web search for hard analyst consensus specific to this print found none (PGHL has only sparse coverage, per the preview's own note of a single analyst rating), so vsStreet is marked unknown rather than inferred. No management press release/commentary beyond the regulatory filing was available to cross-check against print. The quarter's other corporate developments (trading window closure, AGM, director reappointment, dividend record date) are governance/calendar items unrelated to the operating print.
W1
Whether NPM (28.9% this quarter, up from 26.8% YoY) holds into H2 FY27 now that Q1's one-off property-sale gain has fully lapped
W2
Input-cost trend the pre-result preview flagged as the key headwind: cost of materials + traded goods grew well below revenue this quarter — watch if that gap holds next quarter
W3
Whether management finally issues formal FY27 guidance, a watch item our preview specifically flagged and which remains unresolved in this filing
Informational and educational content only. Not investment advice.